Speakers

Hashim is currently Chair of Urology and Head of the Section of Specialty Surgery at Imperial College London which incorporates breast, ENT, head and neck, neurosurgery, ophthalmology, urology and vascular surgery. He heads up the Imperial Prostate group since 2017 when he took up the Chair of Urology having previously been at UCL as a MRC Clinical Research Training Fellow for his PhD, followed by an MRC Clinician Scientist Fellowship which incorporated his position as Clinical Senior Lecturer and then Reader in Urology.

He currently holds a Wellcome Senior Research Fellowship (2017 to 2027). His research interests are in health technology assessment with a strong focus on clinical trials that bring innovative and transformative changes to the prostate cancer pathway from screening through to treatment of advanced disease. This has been and is supported by a grant income over the last 10 years of approximately £50M as lead applicant and £12M as co-applicant. He has well over 400 peer reviewed publications. He is active clinically, dealing with benign and malignant diseases of the prostate within the outpatient setting and operatively with minimally invasive approaches such as HIFU, cryotherapy and Nanoknife for prostate cancer as well as Rezum and laser TURP forbenign enlarged prostates. As a result, he has and continues to train and support numerous urologists internationally in the specialised techniques that he has pioneered.

I am a consultant histopathologist working in Addenbrookes Hospital reporting Urological pathology and Gynae pathology. 

Speaker bio coming soon.

Speaker bio coming soon.

Consultant histopathologist based at Barts Health NHS Trust in London, specialising in uropathology and gastrointestinal pathology.

Dr Ashish Chandra is based at Guy's & St Thomas' NHS Foundation Trust, London and has hosted many of the annual BAUP courses. He has been Chair of BAUP and departmental lead consultant for Uropathology. His special interests include urothelial carcinoma and also cytopathology.

Speaker bio coming soon.

Speaker bio coming soon.

Dr Aiman Haider is a consultant histopathologist (Urological Pathology) in the Department of Cellular Pathology, UCLH, London. She is a Honorary Lecturer; Division of Surgery and Interventional Sciences, Department of Targeted Intervention, UCL, London. She is the Education Secretary of the British Association of Urological Pathologists. 

Glen Kristiansen, M.D., *1969, studied human medicine in Freiburg i.Br., Berlin and London (1988-1995). After completion of his medical thesis (M.D., 2000, biomarkers of NSCLC,) he took  his pathology board examination in 2003 (Charité, Berlin, Germany), followed by the 
post-doctoral thesis 2004 on prostate cancer genes. Clinical focusses are genito-urinary, breast and molecular pathology/immunohistochemistry. 

From 2007-2011 he was professor for molecular cancer research at the Department of Surgical Pathology, University of Zurich (Switzerland). Since 2011 he is full professor and chair of the Institute of Pathology, University of Bonn, Germany. 

Scientifically active in GU pathology and molecular analysis of solid tumors, biomarker research and GU reference pathology (>600 papers, >34.000 citations, H-index 93).

Longstanding lecturing activities in the International Academy of Pathology (IAP), with a focus on prostate pathology. From 2023-2025 he was President of the International Society of Urological Pathology (ISUP) and is currently incoming/designated President of the GD-IAP. 

Dr. Rohit Mehra is a Clinical Professor of Pathology at University of Michigan and Faculty Member of the Michigan Center for Translational Pathology (MCTP). As a genitourinary pathologist, Dr. Mehra serves as a regional and national consultant and regularly reviews extramural consultations. As Genitourinary service line director for MLabs, Michigan Medicine's reference laboratory division, and Director, MCTP Esoteric Clinical Laboratory Services where he oversees the development of novel assays in Genitourinary Oncology, Dr. Mehra works to solve diagnostic problems, both common and rare. He has helped launch clinically significant molecular oncology results into assays for diagnostic, prognostic, and/or therapeutic use (PMIDs: 37499055, 36581128, 36264673, 33854184, others).

Focusing on the discovery of gene aberrations in genitourinary tumors and development of related biomarkers, Dr. Mehra played an important role early on in discovery of recurrent fusion of TMPRSS2 and ETS transcription factor genes (PMIDs: 16254181, 17334343, others). These genes are now recognized as an important driver mutation in prostate cancer. His more recent work has helped characterize uncommon and common renal tumors at the clinicopathologic and molecular level; such tumors include entities like Mucinous Tubular Spindle cell carcinoma, MiTF-altered RCC, ESC RCC, and others (PMID: 35941720, 32299640, 29941307, others). Over the last decades, he has served as the author of more than 300 publications in the peer-reviewed literature, several book chapters, and abstracts. Dr. Mehra has delivered numerous invited national and international presentations.

Participating in projects with, and providing peer-review services to, organizations like the Prostate Cancer Foundation (PCF), Genitourinary Pathology Society (GUPS), International Society of Urologic Pathology (ISUP), United States and Canadian Academy of Pathology (USCAP), Clinical Proteomic Tumor Analysis Consortium (CPTAC) and The Cancer Genome Atlas (TCGA), Dr. Mehra has contributed to several multidisciplinary NIH-funded and non-NIH-funded projects investigating clinical and translational aspects of genitourinary malignancies. For the USCAP specifically, Dr. Mehra has previously served as a member of the abstract review committee, given several genitourinary talks in diverse settings (including the prestigious Arthur Purdy Society lecture in 2021), and presented a renal short course at the 2022-23 international meeting. Currently, Dr. Mehra serves as a member of GUPS Executive Committee and is Chair of GUPS Education Committee. Additionally, Dr. Mehra directs the Michigan Legacy Tissue Program (MLTP, a rapid autopsy-based program) at University of Michigan, which helps patients, and their families make a lasting impact in the lives of future patients, giving others a better chance at life by participating in clinical cancer research.

Professor Caroline Moore is passionate about improving the diagnostic and treatment pathway for men with prostate cancer, using the latest in imaging technology, decision support and outcomes measurement. 

She is Head of Urology, University College London and holds an NIHR Research Professorship to develop BESPOKE – BeSpokE – Building and evaluating a Stratified Prostate Cancer pathway for Screening, Detection, Decision Support and SurveillancE. 

Her work is supported by major funders including Movember, Prostate Cancer UK, the National Institute for Health Research, the Medical Research Council and Cancer Research UK. 

I graduated from Barts and The London Medical College in 1999 and then undertook Urology speciality training in North London. I completed 4 years as an NIHR clinical Lecturer at Cambridge University before my Royal College of Surgeons accredited robotic surgery fellowship. I have been a consultant at University College Hospitals London for 9 years. UCLH is the highest volume centre in the UK for robotic radical prostatectomy and we perform almost 10% of the NHS prostatectomy caseload. I am now Professor of Urology at University College London and Associate lead for Uro oncology and Lead for robotic Urology at UCLH. Alongside my cliical work, I lead a multi-disciplinary research team who are internationally recognised for our groundbreaking work on improving outcomes for men having radical prostatectomy for prostate cancer.

I will present the NeuroSAFE PROOF randomised control trial which was published earlier this year in Lancet Oncology and will describe further work regarding the development of the LASERSAFE, (confocal laser microscopy) technique as a possible alternative to the NeuroSAFE for intra-operative surgical margin evaluation during radical prostatectomy.

Dr Silvanto is a Consultant Histopathologist at UCLH. Since obtaining her CCT in 2013, following postgraduate training in London, she has subspecialised in uropathology, with a specific interest in prostate cancer. 

Dr. Steven C. Smith serves as Professor of Pathology and Surgery, as well as Director of the Immunohistochemical Biomarkers Core at the Virginia Commonwealth University, where he joined the Pathology Department in 2014.  He grew up in Charleston, South Carolina, graduated from the University of Georgia, and then from the US NIH-designated Medical Scientist Training Program at the University of Virginia (MS ’06, PhD ‘08, and MD ‘08) as a member of the University’s Raven Society. After a postdoctoral fellowship at UVA he trained in Anatomic Pathology at the University of Michigan, and in Genitourinary Pathology at Cedars-Sinai Medical Center in Los Angeles with Dr. Mahul Amin.

Dr. Smith has authored >150 peer-reviewed publications and >70 textbook chapters, including in the Diagnostic Pathology: Genitourinary series and as author in multiple editions of the WHO Classification series. He serves in editorial roles and on the board for several journals, and has taught numerous courses at USCAP, ASCP, and IAP meetings in the US, Canada, Europe, Asia, and Australia.  He resides in Richmond, Virginia, with his wife (a Urogynecologist), and children.

Clare Verrill is Professor of Cellular Pathology and Artificial Intelligence with the Nuffield Department of Surgical Sciences at the University of Oxford and Honorary Consultant Cellular Pathologist with Oxford University Hospitals NHS Foundation Trust. Her sub speciality is urological pathology and has her own research group focussing on digital pathology and AI. The NHS Cellular Pathology Laboratory in Oxford has achieved the milestone of scanning 100% of surgical histology workload under her oversight. She was previously Oxford Principal Investigator for Oxford PathLAKE (one of the UK Government’s AI Centres of Excellence) and has worked with computer science partners to develop AI. She is the Principal Investigator of a phase 4 AI in Healthcare study to evaluate Paige Prostate AI in NHS settings. She is a previous Turing Fellow with the Alan Turing Institute.

Completed histopathology training and examinations in India, UK and USA. Author of multiple national and international guidelines, particularly in prostate and bladder. Lead author of RCPath bladder cancer dataset. Passionate proponent of personalised histopathology reporting focussing on clinical utility and communication of histopathology data.

Speaker bio coming soon.